Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Australis Capital Inc. AUSAF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
26/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Australis Capital Inc. (AUSAF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 24/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $8M, +416.8%/yr average growth. Net income is $40M (loss), growing at -175.4%/yr. Net profit margin is -528.7% (negative). Gross margin is 52.4% (-45.8 pp trend).

Balance sheet: total debt is $14M against $21M equity (Debt-to-Equity (D/E) ratio 0.66, moderate). Current ratio is 0.69 (tight liquidity). Debt-to-assets is 27.3%. Total assets: $51M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 25/100 (Fail), Moat 35/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

AUSAF SharesGrow Score Overview

32/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 25/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AUSAF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
AUSAF: +416.8%/yr revenue is, -175.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
25/100
Balance sheet AUSAF: Debt-to-Equity (D/E) ratio 0.66 (moderate), Current ratio is 0.69 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
AUSAF: Gross margin is 52.4% (-45.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
AUSAF: Net profit margin is -528.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.01
Volume90K
Avg Volume (30D)1.49K
Market Cap$5.57K
Beta (1Y)-0.40
Share Statistics
EPS (TTM)-0.16
Shares Outstanding$247.49M
IPO Date2018-09-28
CEOTerrance R. Booth
Financial Highlights & Ratios
Revenue (TTM)$7.57M
Gross Profit$3.97M
EBITDA$-14.13M
Net Income$-40.03M
Operating Income$-19.38M
Total Cash$581.57K
Total Debt$13.8M
Net Debt$13.22M
Total Assets$50.61M
Price / Earnings (P/E)-0
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINCA05259R1073

Price Chart

Track all markets on TradingView
AUSAF
Australis Capital Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.01

People Also View

CNPOF
CNPOF
RIV Capital Inc.
$0.08
+0.00%
 BMMJ
BMMJ
Body and Mind Inc.
$0.00
+0.00%
 RDDTF
RDDTF
Radient Technologies Inc.
$0.00
+0.00%
 CHOOF
CHOOF
Choom Holdings Inc.
$0.00
+0.00%
 KHRNF
KHRNF
Khiron Life Sciences Corp.
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message